Abstract
Purpose
The occurrence of diminished ovarian reserve (DOR) in women was growing in recent years. Although in vitro fertilization and embryo transfer (IVF-ET) became an effective treatment for DOR, the live-birth (LB) rate remains unsatisfactory. This study aimed to investigate the impact factors of LB rate in women with DOR undergoing assisted reproduction.
Methods
This was a single-center retrospective cohort study. A total of 2277 IVF-ET or ICSI cycles from 1957 DOR women were analysed. Impact factors of LB rate were explored via Student’s t test, Pearson’s Chi-square test, and multivariate logistic regression models.
Results
There were statistically significant differences in maternal age (P < 0.001), duration of infertility (P < 0.001), female body mass index (P = 0.039), first IVF cycle (P = 0.004), poor ovarian response (P < 0.001), paternal age (P < 0.001), total gonadotropin dose (P = 0.010), endometrial thickness (P = 0.021), number of follicles ≥ 14 mm (P = 0.007), number of oocytes retrieved (P < 0.001), number of frozen embryos (P = 0.014), and the stage (P < 0.001) and number (P < 0.001) of embryos transferred between the non-live-birth (NLB) and LB groups. However, only factors of maternal age, the stage and number of embryos transferred remained different after adjusting for potential confounders.
Conclusions
Maternal age, the stage and number of embryos transferred were independent impact factors affecting the live-birth rate in women with DOR seeking for assisted conception.
Keywords: Diminished ovarian reserve, Live-birth rate, In vitro fertilization and embryo transfer, Impact factors, Cohort study
Introduction
Ovarian reserve plays a crucial role in menstrual regularity and achieving pregnancy in reproductive-age women. A large number of single or various combined tests have been used for evaluation of the ovarian reserve in an effort to predict the reproductive competence (ovarian response and pregnancy outcome) [1]. The ideal ovarian reserve tests (ORT) could accurately reflect oocytes’ reproductive capacity, and is useful in assisting infertile women with reproductive life planning. Among these ORTs, antral follicle count (AFC), basal serum follicle stimulating hormone (FSH) level, anti-Mullerian hormone (AMH) together with maternal age seem to be the most commonly used tests for detection of ovarian reserve [2]. Diminished ovarian reserve (DOR), with an imprecise definition of a decreased number or quality of oocytes, affects approximately 10% of women seeking fertility treatment [3]. It is associated with poor ovarian response (POR) to controlled ovarian hyperstimulation, and is much more prevalent than premature ovarian failure (POF). The most popular tests used for diagnosing DOR nowadays are AFC and FSH [4]. Other risk or protective factors like maternal age, inhibin B, AMH, ovarian volume, a number of dynamic tests also make contribution to detect DOR [5].
However, few has been known about its etiology until now. It has been reported that there was an association between ABO blood type and DOR occurrence [6, 7]. A retrospective analysis involving 35,479 women who underwent in vitro fertilization and embryo transfer (IVF-ET) cycles showed that women with B antigen (blood type AB or B) were more likely to have DOR [8]. Weghofer et al. reported that there was an association between the age of menarche and DOR risk later in life among infertile women [9]. A recent retrospective case–control study which evaluated differences among causes of DOR showed that DOR women by surgery for endometrioma(s) had significantly lower pregnancy and live-birth rates per cycle compared with patients with idiopathic DOR [10].
Despite of being investigated widely, precise definition and optimal management of DOR remain an unsolved enigma, with no single beneficial intervention having been proposed [11]. Although DOR affects a large portion of the infertile population, there were few studies focusing on the factors influencing their LB rates with assisted reproductive technology (ART).
In the present study, we conducted a retrospective cohort study to investigate the impact factors of live-birth rate in Chinese women with DOR undergoing assistant reproduction, which might shed light on the clinical strategy for DOR women to improve their take-home baby rates.
Materials and methods
Study population
Our study is a retrospective, university hospital-based cohort study, carried out at Women’s Hospital, Zhejiang University School of Medicine. Referring to the Bologna Criteria published in 2011 and clinical experience [12], the inclusion criteria for women with defined diminished ovarian reserve (DOR) in this study were women undergoing fresh IVF or intracytoplastic sperm injection (ICSI) with (1) age ≥ 40 years on day 1 of gonadotropin stimulation, and/or (2) serum basal follicle stimulating hormone (bFSH) level ≥ 10 IU/L, and/or (3) bilateral antral follicle count (AFC) < 5 follicles.
To minimize the potential confounding factors, exclusion criteria of subjects were as follows: (1) donor oocytes/sperm cycles, or (2) embryo recipient cycles, or (3) women who applied for pre-implantation genetic diagnosis/screening (PGD/PGS), or (4) women with unilateral ovary, chronic hypertension, diabetes, or heart disease, or (5) women with canceled or all-frozen embryo transfer cycles.
A total of 2277 cycles from 1957 DOR women who underwent IVF-ET or ICSI cycles between January 2010 and December 2014 were enrolled from our medical database. Available information on the dataset included maternal factors (maternal age, age of menarche, body mass index, duration of infertility, first IVF cycle,poor ovarian response, antral follicle count, serum hormone levels, and type of infertility), paternal factors (paternal age, semen volume, and sperm motility), ART procedure (type of ART, total gonadotropin dose, duration of ovarian stimulation, endometrial thickness, number of follicles ≥ 14 mm, number of oocytes retrieved, number of frozen embryos, and the number and stage of embryos transferred), and ART outcomes (clinical pregnancy, live birth, pre-term birth, multiple pregnancies, low birth weight, and miscarriages).
The strategy of our reproductive center on the number of embryos transferred is in accordance with the regulation by Chinese government. Usually, no more than two embryos were transferred. And elective single embryo transfer is suggested when the woman is young (< 30 years), having more than three good-quality embryos, and having no unfavorable prognosis factors, e.g., recurrent implantation failure or recurrent miscarriage. However, three embryos were sometimes allowed to be transferred in women older than 35 years with prior unsuccessful transfer cycle, after counseling the patient on the risk of multiple gestation.
All the clinical and laboratory data were extracted from the historical medical records based on the Hospital Information System (HIS) in Women’s Hospital, Zhejiang University School of Medicine. All private information of names, residential addresses, telephone numbers and Resident Identification Card numbers were kept strictly confidential and were masked in the data analysis. Specific subject could not be identified. The Research Ethics Board of Women’s Hospital, Zhejiang University School of Medicine granted ethics approval and waived informed consent.
Outcome measures
Primary outcome was live-birth rate. Secondary measures consisted of clinical pregnancy (CP), pre-term birth (PB), multiple pregnancies (MP), miscarriages (M), and low birth-weight (LBW) rates. Serum β human chorionic gonadotropin (β-hCG) was tested 14 days after embryo transfer, and for those with a positive β-hCG test, ultrasonography was performed 35 days after embryo transfer.
We defined the pregnancy outcomes in this study according to “International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary of ART Terminology, 2009” [13]:
Clinical pregnancy: serological β-hCG positive 14 days after embryo transfer, and after transplantation ultrasonography visualization of one or more gestational sacs, including ectopic pregnancy, after 30–35 days of transplantation.
Implantation rate: the ratio of the number of embryos implanted to the total number of embryos transferred.
Clinical pregnancy rate: the ratio of the number of clinical pregnancy cycles to the total number of transfer cycles.
Miscarriage: identified as clinical pregnancy, but the pregnancy spontaneously terminated in less than 28 weeks. Early miscarriage occurred in less than 14 weeks.
Miscarriage rate: the ratio of the number of miscarriage cycles to the total number of transfer cycles.
Preterm delivery: delivered after 28 weeks but before 37 weeks.
Low birth weight (LBW): birth weight less than 2500 g.
Statistical analysis
Statistical analyses were performed with Statistical Package for the Social Sciences software (SPSS version 20.0; IBM/SPSS, Inc.). The continuous variables were summarized as mean ± standard deviation (SD) and were tested by unpaired Student’s t test. Dichotomous data were shown as percentages. Differences between categorical variables were tested using Pearson’s Chi-square test. The characteristics that were significantly different (P < 0.05) between the LB and non-live-birth (NLB) groups were then selected to construct logistic regression models. Both univariable and multivariate logistic regression models were employed to evaluate the impact of variables of interest on odds of live birth after assisted reproduction in women with DOR. Two-sided P values of less than 0.05 were considered statistically significant.
Results
Totally, 4632 cycles were assessed for eligibility during January 2010–December 2014 (Fig. 1). We dropped those with IVF-ET cycles canceled (n = 631), frozen embryo(s) transferred (n = 908) and missing data on follow-up (n = 231), as well as those meeting the exclusion criteria of donor oocytes/sperm (n = 283), single ovary (n = 38), chronic hypertension (n = 142), diabetes mellitus or heart diseases (n = 55) and PGD/PGS (n = 67). Finally, 2277 cycles were remained for analyses, and were divided into two groups, including live-birth group (LB, n = 504) and non-live-birth group (NLB, n = 1773). All the eligible cycles consisted of 567 women aged at least 40 years, 1291 women with bilateral AFC counts of < 5 follicles and 916 women with bFSH levels of ≥ 10 IU/L.
Fig. 1.
Flow chart of context diagram in the study. IVF-ET in vitro fertilization-embryo transfer, PGD pre-implantation genetic diagnosis, PGS pre-implantation genetic screening, bFSH basal follicle stimulating hormone, AFC antral follicle count
Baseline characteristics and clinical outcomes of DOR women undergoing IVF or ICSI grouped according to live birth
As shown in Table 1, we found statistically significant differences in maternal age (35.06 ± 5.53 vs 32.61 ± 4.70 years, P < 0.001), duration of infertility (5.41 ± 4.19 vs 4.67 ± 3.45 years, P < 0.001), female body mass index (BMI, 22.31 ± 2.87 vs 22.01 ± 3.11 kg/m2, P = 0.039), first IVF cycle (P = 0.004), poor ovarian response (P < 0.001), paternal age (36.78 ± 6.16 vs 34.55 ± 5.48 years, P < 0.001), total gonadotropin dose (2610.74 ± 1097.89 vs 2494.07 ± 819.95 IU, P = 0.010), endometrial thickness on the day of human chorionic gonadotropin (hCG) triggering injection (10.38 ± 2.17 vs 10.63 ± 2.25 mm, P = 0.021), number of follicles ≥ 14 mm on triggering day (5.80 ± 3.72 vs 6.31 ± 3.20, P = 0.007), number of oocytes retrieved (7.24 ± 4.76 vs 8.30 ± 4.42, P < 0.001), number of frozen embryos (0.83 ± 1.77 vs 1.12 ± 1.91, P = 0.014), and the stage (P < 0.001) and number of embryos transferred (P < 0.001) between the NLB and LB groups. The median number of oocytes retrieved was 7 [inter-quartile range (IQR) 4–10; Fig. 2a], and the median maternal age was 34 years (IQR 30–39; Fig. 2b) in all studied cycles. Distributions of the number of oocytes retrieved and maternal age in the LB group were elucidated in Fig. 2c, d. Nevertheless, we found no statistically significant differences in the age of menarche, AFC, basal serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P) and testosterone (T), semen volume, sperm motility [represented by the rate of progressive relativity (PR) in sperm], type of ART, type of infertility, duration of ovarian stimulation, transfer embryo(s) at least one 8CII rate, and serum P and E2 levels on triggering day between the study groups (P > 0.05, respectively).
Table 1.
Baseline characteristics and IVF outcomes of DOR women undergoing IVF-ET
| All (n = 2277) | NLB (n = 1773) | LB (n = 504) | P value | |
|---|---|---|---|---|
| Maternal age (years, mean ± SD) | 34.52 ± 5.46 | 35.06 ± 5.53 | 32.61 ± 4.70 | < 0.001 |
| Age at menarche (years, mean ± SD) | 14.44 ± 1.32 | 14.36 ± 1.32 | 14.79 ± 1.29 | 0.096 |
| Body mass index (kg/m2, mean ± SD) | 22.25 ± 2.93 | 22.31 ± 2.87 | 22.01 ± 3.11 | 0.039 |
| Duration of infertility (years, mean ± SD) | 5.24 ± 4.05 | 5.41 ± 4.19 | 4.67 ± 3.45 | < 0.001 |
| First IVF cycle | 0.004 | |||
| Yes [n (%)] | 1614 (70.9) | 1231 (69.4) | 383 (76.0) | |
| No [n (%)] | 663 (29.1) | 542 (30.6) | 121 (24.0) | |
| Poor ovarian response | < 0.001 | |||
| Yes [n (%)] | 478 (21.0) | 416 (23.5) | 62 (12.3) | |
| No [n (%)] | 1799 (79.0) | 1357 (76.5) | 442 (87.7) | |
| Antral follicle count (n, mean ± SD) | 4.98 ± 3.26 | 5.01 ± 3.32 | 4.88 ± 3.06 | 0.438 |
| Basal FSH (IU/L, mean ± SD) | 9.16 ± 3.91 | 9.20 ± 3.81 | 9.01 ± 4.27 | 0.336 |
| Basal LH (IU/L, mean ± SD) | 4.88 ± 2.63 | 4.87 ± 2.58 | 4.93 ± 2.78 | 0.638 |
| Basal E2 (pmol/L, mean ± SD) | 136.42 ± 91.79 | 138.21 ± 90.02 | 130.14 ± 97.57 | 0.082 |
| Basal P (nmol/L, mean ± SD) | 1.74 ± 1.12 | 1.72 ± 1.14 | 1.78 ± 1.03 | 0.408 |
| Basal T (nmol/L, mean ± SD) | 0.86 ± 1.03 | 0.84 ± 1.00 | 0.92 ± 1.12 | 0.218 |
| Paternal age (years, mean ± SD) | 36.28 ± 6.08 | 36.78 ± 6.16 | 34.55 ± 5.48 | < 0.001 |
| Semen volume (ml, mean ± SD) | 2.94 ± 1.94 | 2.98 ± 2.12 | 2.81 ± 1.12 | 0.602 |
| The rate of PR in sperm (%) | 40.54 ± 13.82 | 40.25 ± 13.77 | 41.59 ± 14.03 | 0.379 |
| Type of ART | 0.058 | |||
| IVF cases [n (%)] | 1749 (76.8) | 1346 (75.9) | 403 (80.0) | |
| ICSI cases [n (%)] | 528 (23.2) | 427 (24.1) | 101 (20.0) | |
| Type of infertility | 0.987 | |||
| Primary infertility [n (%)] | 808 (35.5) | 629 (35.5) | 179 (35.5) | |
| Secondary infertility [n (%)] | 1469 (64.5) | 1144 (64.5) | 325 (64.5) | |
| Total gonadotropin dose (IU, mean ± SD) | 2585.06 ± 1044.05 | 2610.74 ± 1097.89 | 2494.07 ± 819.95 | 0.010 |
| Duration of stimulation (days, mean ± SD) | 9.45 ± 2.28 | 9.44 ± 2.35 | 9.47 ± 1.99 | 0.750 |
| Endometrial thickness on day of hCG (mm, mean ± SD) | 10.43 ± 2.19 | 10.38 ± 2.17 | 10.63 ± 2.25 | 0.021 |
| P levels on triggering day (nmol/L, mean ± SD) | 2.22 ± 1.09 | 2.23 ± 1.11 | 2.19 ± 1.00 | 0.387 |
| E2 levels on triggering day (pmol/L, mean ± SD) | 8477.49 ± 5800.58 | 8405.62 ± 5956.00 | 8731.67 ± 5211.58 | 0.240 |
| Number of follicles ≥ 14 mm (n, mean ± SD) | 5.91 ± 3.62 | 5.80 ± 3.72 | 6.31 ± 3.20 | 0.007 |
| Number of oocytes retrieved (n, mean ± SD) | 7.47 ± 4.71 | 7.24 ± 4.76 | 8.30 ± 4.42 | < 0.001 |
| Embryo stage | < 0.001 | |||
| Day 2 [n (%)] | 815 (35.8) | 692 (39.0) | 123 (24.4) | |
| Day 3 [n (%)] | 1462 (64.2) | 1081 (61.0) | 381 (75.6) | |
| Number of embryos transferred | < 0.001 | |||
| One [n (%)] | 490 (21.5) | 443 (25.0) | 47 (9.3) | |
| Two [n (%)] | 1103 (48.4) | 810 (45.7) | 293 (58.1) | |
| Three [n (%)] | 684 (30.0) | 520 (29.3) | 164 (32.5) | |
| Transfer embryo(s) at least one 8CII | 0.546 | |||
| Yes [n (%)] | 1057 (46.4) | 829 (46.8) | 228 (45.2) | |
| No [n (%)] | 1220 (53.6) | 944 (53.2) | 276 (54.8) | |
| Number of frozen embryos (n, mean ± SD) | 0.90 ± 1.81 | 0.83 ± 1.77 | 1.12 ± 1.91 | 0.014 |
SD standard deviation, DOR diminished ovarian reserve, ART assisted reproductive technology, IVF-ET in vitro fertilization-embryo transfer, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection, LB live birth, NLB non-live birth, FSH follicle stimulating hormone, LH luteinizing hormone, E2 estradiol. P progesterone, T testosterone, hCG human chorionic gonadotropin, PR progressive relativity
Fig. 2.
Distributions of oocytes retrieved and maternal age in all studied cycles and the live-birth (LB) group. a Distribution of oocytes retrieved in all studied cycles; b distribution of maternal age in all studied cycles; c distribution of oocytes retrieved in the LB group; d distribution of maternal age in the LB group
Relationship between the impact factors affecting LB in DOR women undergoing IVF or ICSI
In subsequent analyses, we performed univariable and multivariate logistic regression analyses to assess if those impact factors remained different between the two groups after adjusting for potential confounders (Table 2). In this regression analysis, we accounted for thirteen variables that were unevenly distributed (P < 0.05) between the LB and NLB groups in Table 1. After adjusting for potential confounders, factors of BMI [adjusted odds ratio (aOR) 1.02, 95% confidence interval (CI) 0.97–1.06; P = 0.461], duration of infertility (aOR 0.99, 95% CI 0.95–1.03; P = 0.542), paternal age (aOR 0.98, 95% CI 0.95–1.01; P = 0.188), total gonadotropin dose (aOR 0.92, 95% CI 0.81–1.04; P = 0.167), endometrial thickness on the day of hCG triggering injection (aOR 1.03, 95% CI 0.97–1.09; P = 0.322), number of follicles ≥ 14 mm on triggering day (aOR 0.97, 95% CI 0.92–1.03; P = 0.382), number of oocytes retrieved (aOR 0.98, 95% CI 0.93–1.04; P = 0.540), first IVF cycle (aOR 1.30, 95% CI 0.94–1.79; P = 0.109),poor ovarian response (aOR 0.91, 95% CI 0.57–1.44; P = 0.686), and the number of frozen embryos (aOR 1.09, 95% CI 1.00–1.18; P = 0.060) were not significantly associated with live birth among DOR women undergoing IVF or ICSI. Meanwhile, we found that compared with subjects with age of ≤ 30 years, those in the age group of ≥ 40 years (aOR 0.26, 95% CI 0.14–0.47; P < 0.001) suffered from decreased LB rate. Besides, cycles with embryo stage of day 3 were related with increased likelihoods of LB (aOR 1.53, 95% CI 1.13–2.08; P = 0.006). When set women with one embryo transferred as reference, the fully aORs (95% CI) of LB were 2.53 (1.62–3.97) and 4.59 (2.73–7.70) for two and three embryos transferred, respectively. Hence, factors of maternal age, the stage and number of embryos transferred may independently affect the IVF-ET live-birth rates in women with DOR.
Table 2.
Odd ratios for live birth in DOR women undergoing IVF-ET
| Crude OR (95% CI) | P value | Adjusted OR (95% CI) | Adjusted P value | |
|---|---|---|---|---|
| Maternal age (years) | ||||
| ≤ 30 | Reference | Reference | ||
| 31–34 | 0.80 (0.62–1.03) | 0.083 | 0.87 (0.60–1.25) | 0.442 |
| 35–39 | 0.60 (0.46–0.78) | < 0.001 | 0.74 (0.46–1.18) | 0.203 |
| ≥ 40 | 0.23 (0.16–0.32) | < 0.001 | 0.26 (0.14–0.47) | < 0.001 |
| Body mass index (kg/m2) | 0.96 (0.93–1.00) | 0.039 | 1.02 (0.97–1.06) | 0.461 |
| Duration of infertility (years) | 0.95 (0.93–0.98) | < 0.001 | 0.99 (0.95–1.03) | 0.542 |
| Paternal age (years) | 0.94 (0.92–0.96) | < 0.001 | 0.98 (0.95–1.01) | 0.188 |
| Total gonadotropin dose (IU) | 0.92 (0.84–1.01) | 0.064 | 0.92 (0.81–1.04) | 0.167 |
| Endometrial thickness on day of hCG (mm) | 1.06 (1.01–1.10) | 0.021 | 1.03 (0.97–1.09) | 0.322 |
| Number of follicles ≥ 14 mm (n) | 1.04 (1.01–1.07) | 0.009 | 0.97 (0.92–1.03) | 0.382 |
| Number of oocytes retrieved (n) | 1.05 (1.03–1.07) | < 0.001 | 0.98 (0.93–1.04) | 0.540 |
| First IVF cycle (n) | 1.39 (1.11–1.75) | 0.004 | 1.30 (0.94–1.79) | 0.109 |
| Poor ovarian response (n) | 0.46 (0.34–0.61) | < 0.001 | 0.91 (0.57–1.44) | 0.686 |
| Number of frozen embryos (n) | 1.08 (1.02–1.15) | 0.010 | 1.09 (1.00–1.18) | 0.060 |
| Embryo stage (n) | ||||
| Day 2 | Reference | Reference | ||
| Day 3 | 1.98 (1.58–2.48) | < 0.001 | 1.53 (1.13–2.08) | 0.006 |
| Number of embryos transferred (n) | ||||
| One | Reference | Reference | ||
| Two | 3.41 (2.45–4.74) | < 0.001 | 2.53 (1.62–3.97) | < 0.001 |
| Three | 2.97 (2.10–4.21) | < 0.001 | 4.59 (2.73–7.70) | < 0.001 |
Multivariate logistic regression analysis was conducted accounting for potential confounders within the cycles performed in our center
OR odds ratio, CI confidence interval, DOR diminished ovarian reserve, IVF-ET in vitro fertilization and embryo transfer, hCG human chorionic gonadotropin
Comparisons of ART outcomes in DOR women stratified by maternal age, embryo stage, and the number of embryos transferred
We further conducted stratification analyses by maternal age, and the stage and number of embryos transferred to compare ART outcomes (including CP, clinical pregnancy; LB, live birth; PB, pre-term birth; MP, multiple pregnancies; LBW, low birth weight; M, miscarriages) in DOR women (Fig. 3). Either in the 2277 cycles or in the 1614 first IVF cycles, the CP, LB, and MP rates were statistically higher in the < 35 years age group compared with the ≥ 35 years age group (Fig. 3a, d); the CP and LB rates were statistically higher in the day 3 embryo stage group compared with the day 2 group (Fig. 3b, e). There were significantly higher CP and LB rates among patients transferred with three or two embryos compared to those with one embryo; however, the multiple pregnancies and miscarriages rates also increased (Fig. 3c, f). The LB rates were 31.0% (184/593), 26.4% (152/575), 21.2% (115/542), and 9.3% (53/567) among DOR women in the age groups of ≤ 30 years, 31–34 years, 35–39 years, and ≥ 40 years, respectively (Fig. 4a), and the LB rates were 9.2% (32/348), 28.2% (146/517), 27.5% (263/958), and 13.9% (63/454) in the DOR subgroups of age ≥ 40 years, bFSH ≥ 10 IU/L, AFC < 5 follicles, and multiple factors, respectively (Fig. 4b).
Fig. 3.
Comparisons of ART outcomes in DOR women stratified by maternal age, embryo stage, and the number of embryos transferred. CP clinical pregnancy, LB live birth, PB pre-term birth, MP multiple pregnancies, LBW low birth weight, M miscarriages, ART assisted reproductive technology, DOR diminished ovarian reserve. a, d Comparison of ART outcomes in DOR women stratified by maternal age; b, e comparison of ART outcomes in DOR women stratified by embryo stage; c, f comparison of ART outcomes in DOR women stratified by the number of embryos transferred. a–c In the 2277 cycles; d–f in the 1614 first IVF cycles. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 4.
LB rates of DOR women according to different age groups and DOR subgroups. LB live birth, NLB non-live birth, DOR diminished ovarian reserve, bFSH basal follicle stimulating hormone, AFC antral follicle count. a The LB rates were 31.0%, 26.4%, 21.2%, and 9.3% among DOR women in the age groups of ≤ 30 years, 31–34 years, 35–39 years, and ≥ 40 years, respectively. b The LB rates were 9.2%, 28.2%, 27.5%, and 13.9% in the DOR subgroups of age ≥ 40 years, bFSH ≥ 10 IU/L, AFC < 5 follicles, and multiple factors, respectively. *P < 0.05; ***P < 0.001
Comparisons of the number of embryos available for transfer in DOR women according to clinical pregnancy and live birth
As the number of surplus embryos showed borderline significance, we further performed analyses on the number of embryos available for transfer (embryos that were transferred plus those that were frozen) according to clinical pregnancy and live birth. As shown in Fig. 5a, there were statistically significant differences in the number of embryos available for transfer between the live birth and non-live birth groups (2.98 ± 1.73 vs 2.61 ± 1.67, P < 0.001) and the clinical pregnancy and non-clinical pregnancy groups (2.93 ± 1.66 vs 2.59 ± 1.69, P < 0.001). We also conducted an analysis on the implantation rate (number of embryos implanted/total number of embryos transferred). As shown in Fig. 5b, there were statistically significant differences in implantation rates between the live birth and non-live birth groups (14.0% vs 17.2%, P = 0.010) and the clinical pregnancy and non-clinical pregnancy groups (14.5% vs 17.4%, P = 0.011).
Fig. 5.
Comparisons of the number of embryos available for transfer and implantation rates in DOR women according to clinical pregnancy and live birth. DOR diminished ovarian reserve. a There were statistically significant differences in the number of embryos available for transfer between the live birth and non-live birth groups (2.98 ± 1.73 vs 2.61 ± 1.67, P < 0.001) and the clinical pregnancy and non-clinical pregnancy groups (2.93 ± 1.66 vs 2.59 ± 1.69, P < 0.001). b There were statistically significant differences in implantation rates between the live birth and non-live birth groups (14.0% vs 17.2%, P = 0.010) and the clinical pregnancy and non-clinical pregnancy groups (14.5% vs 17.4%, P = 0.011). *P < 0.05, ***P < 0.001
Discussion
Infertility is a major public health problem with a growing occurrence rate over the last decade. Despite rapid advancement in infertility treatments, there are still a large number of infertile women experiencing unsatisfying clinical outcomes from assisted conception treatment. For infertile couples seeking for ART treatment, the most important issue is to have a live birth; thus, it is mandatory to search for a method with maximum efficacy and minimum expense to improve the take-home baby rates. There were few published studies evaluating the impact factors, predictors or key factors of live-birth rate after ART, and a multivariate logistic regression analysis of factors affecting the live-birth rate of DOR patients in ART conceptions has not been previously performed. This retrospective cohort study addresses factors affecting the live-birth rate of DOR women undergoing fresh embryo transfer following IVF or ICSI, and provides valuable information for reproductive clinicians to improve the clinical ART management, and the following live-birth outcome.
It is widely accepted that age alone has an effect on fertility. Moreover, maternal age remains the most valuable factor predictive for the duration of reproductive life span [14]. For DOR women, our study demonstrated that the live-birth rate decreased with the increase of age, especially for those of ≥ 40 years old. We observed that there were statistically significant differences between the LB and NLB groups in both maternal and paternal age (P < 0.001, respectively). However, after adjusting for confounding variables, only maternal age remained different in the multivariate logistic regression model. Nowadays, socioeconomic changes have caused a growing trend for women all over the world to delay parenthood until later ages, which contributes to increased incidence of subfertility and an increasing number of advanced maternal age women opting for fertility treatments. Although ovary is the main determinant of female reproductive aging, uterine factors are also additional contributors [15]. Advanced maternal age is related to many adverse factors affecting the quality of oocyte, including cytoplasm (abnormalities of the cytoskeleton, reduction in mitochondrial number), nucleus (abnormal spindle formation, aneuploidy), and zona pellucida functions [16, 17]. In consistent of our study, Mutlu et al. reported in a prospective study including 192 infertile patients that age was independent predictor of live birth [18], which was closely associated with chromosomal abnormalities and mitochondrial DNA mutations in oocytes for women of advanced maternal age [19, 20]. For DOR women with infertility, the acceptable option is to seek assisted reproduction as soon as they are diagnosed, instead of long-term conception attempt without interfere or consultation from reproductive clinicians.
A case–control study reported that the basal T level presented a positive association with pregnancy outcome in women with DOR [21]. Conversely, there was no statistically significant difference in serum basal T level between the two study groups in our study (0.92 ± 1.12 vs 0.84 ± 1.00 nmol/L; P = 0.218). We also found that serum basal E2 levels were marginally higher in the NLB group in crude analysis (138.21 ± 90.02 vs 130.14 ± 97.57 pmol/L, P = 0.082), but the difference was not statistically significant. This finding is in accordance with a previous study which reported that serum E2 had no correlation with LB rate [22]. Baker et al. found a negative association between gonadotropin dose and LB after IVF treatment, which was consistent with our study [23]. Previous studies documented the influence of female BMI on IVF outcomes, reporting that BMI may affect pregnancy outcome independently [24, 25]. Of note, the present study showed that for DOR women, the LB group had statistically lower BMI (22.01 ± 3.11 vs 22.31 ± 2.87 kg/m2; P = 0.039). However, further regression analysis after adjusting for potential confounders showed that it was not an independent impact factor affecting the IVF-ET live-birth rate in women with DOR. Dokras reported a significantly higher risk for IVF cycle cancelation in obese patients, however, with no effect of BMI on clinical pregnancy or live-birth rate [26]. Disparities among different studies may be resorted to the differences in study designs, sample sizes, populations, physical conditions of women with DOR, and analytical methods.
We found that there were statistically significant differences in implantation rates in DOR women according to the outcomes of clinical pregnancy and live birth. However, the non-live birth group and the non-clinical pregnancy group had higher implantation rates compared to the live birth group (17.2% vs 14.0%, P = 0.010) and the clinical pregnancy group (17.4% vs 14.5%, P = 0.011), respectively. We speculate that the reason of higher implantation rates in the non-live birth group and the non-clinical pregnancy group could be explained by the proportion of age-specific miscarriages in older women, especially for those of ≥ 40 years old. Advanced maternal age women made up a large proportion in the non-live birth group (29.0% vs 10.5%, P < 0.001) compared to the live birth group, and the non-clinical pregnancy group (28.9% vs 15.9%, P < 0.001) compared to the clinical pregnancy group.
Recommendations have been generally intended for cleavage-stage embryos transferred on day 2 or 3 [27], while many reproductive medical centers prefer to transfer blastocyst-stage embryos [28]. To date, the optimal time for selecting embryo(s) to transfer is mixed. It was documented that the probability of live-birth was significantly higher after blastocyst-stage embryo transfer compared to cleavage-stage embryo transfer [29]. However, De Vos A et al. suggested that the choice of embryo transfer day seemed to play no roles on the chances of having a live-born child [30]. We observed that there was a significantly higher clinical pregnancy and live-birth rates among patients with embryos transferred on day 3 compared with day 2.
Furthermore, there were significantly higher clinical pregnancy and live-birth rates among patients transferred with three or two embryos compared to those with one embryo; however, the multiple pregnancies and miscarriages rates also increased simultaneously. Ideally, the aim of ART is to achieve a healthy singleton gestation [31, 32]. The American Society of Reproductive Medicine (ASRM)’s guidelines for the number of embryos to be transferred have been further refined in continuing efforts to decrease the number of multiple pregnancies [33], since multiple gestations lead to a higher risk of maternal and live-birth complications [34]. Among patients younger than 35 years of age undergoing IVF treatment with a favorable prognosis, a single embryo transfer has the highest chance of good perinatal outcome [35]. Therefore, based on our results, we do not recommend women with DOR to transfer high embryo numbers merely to improve clinical pregnancy rate, while regardless of live-birth rates or following obstetric outcomes.
Since the present study is a 5-year, single-center retrospective cohort study, there were limitations which cannot be ignored, in spite of a relatively large number of subjects reviewed. The potential unmeasured confounding factors, insufficient data concerning the definite diagnosis of DOR, and the retrospective design itself may all add to the uncertainty of the results. Furthermore, we only evaluated the impact factors affecting the live-birth rate of fresh embryo transfer cycles in DOR women and, hence, the results cannot be extrapolated to frozen embryo transfer cycles or normal ovarian reserve women. The study was conducted in a single reproductive medical center with standardized laboratory techniques, ovarian stimulation protocols, and embryo transfer procedures. Therefore, multi-center based randomized controlled trials (RCTs) with better planning are suggested in the future study. Further research with in vivo and in vitro models should be undertaken to explore the molecular mechanisms underlying this variation in live-birth outcome of infertile women with DOR in the future. Moreover, we will explore the intriguing association between blastocyst-stage embryos transfer and live-birth rates, as well as perinatal and neonatal outcomes in DOR women further in the follow-up study.
In summary, after adjusting for potential confounding factors, we observed that the maternal age, the embryo stage, and the number of embryos transferred were the independent impact factors affecting the IVF or ICSI live-birth rates in women with DOR. We do not recommend increasing the number of embryos transferred blindly to improve pregnancy rates. The results of this study are helpful for women with DOR and reproductive physicians to have a better understanding of the importance of female age, and the stage and number of embryos transferred on the specific ART outcomes. Efforts should be focused on factors that seem to be mostly predictive of live birth to improve take-home baby rates in the future.
Acknowledgements
The authors are grateful to Saijun Sun and Xiaofei Huang, who aided in the collection of original data. We would like to thank all of our colleagues for providing help during the data collection.
Author contributions
DZ: conception and design of the study. YH, YFL, YQW, FZ: data collection. FZ, JYL, RJZ, JL, KC, WZ, WW, YJH: follow-up of enrolled subjects. YH, JYL, YFL, GFX: analysis and interpretation of data. JG, GDC: statistical analysis of data. YH and JYL drafted the article, and DZ revised it critically. All authors reviewed the manuscript and approved the version to be published.
Funding
This study was supported by the National Key Research and Development Program of China (2017YFC1001003), the National Natural Science Foundation of China (no. 81471421), the Natural Science Foundation of Zhejiang Province (no. LZ18H040001), the Zhejiang Provincial Key Medical Technology Program (no. WKJ-ZJ-1826), and the Zhejiang Provincial College Students’ Science and Technology Innovation Activity Plan (no. 2017R401267).
Informed consent
For this type of study formal consent is not required.
Conflict of interest
The authors have no conflicts of interest to declare.
References
- 1.te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8(2):141–154. doi: 10.1093/humupd/8.2.141. [DOI] [PubMed] [Google Scholar]
- 2.Mutlu MF, Erdem A. Evaluation of ovarian reserve in infertile patients. J Turk Ger Gynecol Assoc. 2012;13(3):196–203. doi: 10.5152/jtgga.2012.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Greene AD, Patounakis G, Segars JH. Genetic associations with diminished ovarian reserve: a systematic review of the literature. J Assist Reprod Genet. 2014;31(8):935–946. doi: 10.1007/s10815-014-0257-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Papathanasiou A, Searle BJ, King NM, Bhattacharya S. Trends in ‘poor responder’ research: lessons learned from RCTs in assisted conception. Hum Reprod Update. 2016 doi: 10.1093/humupd/dmw001. [DOI] [PubMed] [Google Scholar]
- 5.Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685–718. doi: 10.1093/humupd/dml034. [DOI] [PubMed] [Google Scholar]
- 6.Timberlake KS, Foley KL, Hurst BS, Matthews ML, Usadi RS, Marshburn PB. Association of blood type and patient characteristics with ovarian reserve. Fertil Steril. 2013;100(6):1735–1739. doi: 10.1016/j.fertnstert.2013.08.027. [DOI] [PubMed] [Google Scholar]
- 7.Nejat EJ, Jindal S, Berger D, Buyuk E, Lalioti M, Pal L. Implications of blood type for ovarian reserve. Hum Reprod. 2011;26(9):2513–2517. doi: 10.1093/humrep/der199. [DOI] [PubMed] [Google Scholar]
- 8.Lin S, Li R, Chi H, Huang S, Zhang H, Zheng X, Liu P, Qiao J. Effect of ABO blood type on ovarian reserve in Chinese women. Fertil Steril. 2014;102(6):1729–1732. doi: 10.1016/j.fertnstert.2014.09.008. [DOI] [PubMed] [Google Scholar]
- 9.Weghofer A, Kim A, Barad DH, Gleicher N. Age at menarche: a predictor of diminished ovarian function? Fertil Steril. 2013;100(4):1039–1043. doi: 10.1016/j.fertnstert.2013.05.042. [DOI] [PubMed] [Google Scholar]
- 10.Roustan A, Perrin J, Debals-Gonthier M, Paulmyer-Lacroix O, Agostini A, Courbiere B. Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome. Hum Reprod. 2015;30(4):840–847. doi: 10.1093/humrep/dev029. [DOI] [PubMed] [Google Scholar]
- 11.Cohen J, Chabbert-Buffet N, Darai E. Diminished ovarian reserve, premature ovarian failure, poor ovarian responder—a plea for universal definitions. J Assist Reprod Genet. 2015;32(12):1709–1712. doi: 10.1007/s10815-015-0595-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, EwgoPOR Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–1624. doi: 10.1093/humrep/der092. [DOI] [PubMed] [Google Scholar]
- 13.Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Vanderpoel S, International Committee for Monitoring Assisted Reproductive T. World Health O International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009;92(5):1520–1524. doi: 10.1016/j.fertnstert.2009.09.009. [DOI] [PubMed] [Google Scholar]
- 14.American College of O. Gynecologists Committee on Gynecologic P. Practice C. College American. Female age-related fertility decline. Committee Opinion no. 589. Fertil Steril. 2014;101(3):633–634. doi: 10.1016/j.fertnstert.2013.12.032. [DOI] [PubMed] [Google Scholar]
- 15.Nelson SM, Telfer EE, Anderson RA. The ageing ovary and uterus: new biological insights. Hum Reprod Update. 2013;19(1):67–83. doi: 10.1093/humupd/dms043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Barroso G, Taylor S, Morshedi M, Manzur F, Gavino F, Oehninger S. Mitochondrial membrane potential integrity and plasma membrane translocation of phosphatidylserine as early apoptotic markers: a comparison of two different sperm subpopulations. Fertil Steril. 2006;85(1):149–154. doi: 10.1016/j.fertnstert.2005.06.046. [DOI] [PubMed] [Google Scholar]
- 17.Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30(5):465–493. doi: 10.1210/er.2009-0006. [DOI] [PubMed] [Google Scholar]
- 18.Mutlu MF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, Oktem M. Antral follicle count determines poor ovarian response better than anti-Mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet. 2013;30(5):657–665. doi: 10.1007/s10815-013-9975-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hassold T, Hall H, Hunt P. The origin of human aneuploidy: where we have been, where we are going. Human Mol Genet. 2007;16(Spec No. 2):R203–R208. doi: 10.1093/hmg/ddm243. [DOI] [PubMed] [Google Scholar]
- 20.Bartmann AK, Romao GS, Ramos Eda S, Ferriani RA. Why do older women have poor implantation rates? A possible role of the mitochondria. J Assist Reprod Genet. 2004;21(3):79–83. doi: 10.1023/B:JARG.0000027018.02425.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lu Q, Shen H, Li Y, Zhang C, Wang C, Chen X, Liang R, Wei L. Low testosterone levels in women with diminished ovarian reserve impair embryo implantation rate: a retrospective case-control study. J Assist Reprod Genet. 2014;31(4):485–491. doi: 10.1007/s10815-014-0186-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Huang R, Fang C, Wang N, Li L, Yi Y, Liang X. Serum estradiol level change after human chorionic gonadotropin administration had no correlation with live birth rate in IVF cycles. Eur J Obstet Gynecol Reprod Biol. 2014;178:177–182. doi: 10.1016/j.ejogrb.2014.02.040. [DOI] [PubMed] [Google Scholar]
- 23.Baker VL, Brown MB, Luke B, Smith GW, Ireland JJ. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. Fertil Steril. 2015;104(5):1145–1152. doi: 10.1016/j.fertnstert.2015.07.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Rabinson J, Meltcer S, Zohav E, Gemer O, Anteby EY, Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome. Fertil Steril. 2008;89(2):472–474. doi: 10.1016/j.fertnstert.2007.03.007. [DOI] [PubMed] [Google Scholar]
- 25.Zhang D, Zhu Y, Gao H, Zhou B, Zhang R, Wang T, Ding G, Qu F, Huang H, Lu X. Overweight and obesity negatively affect the outcomes of ovarian stimulation and in vitro fertilisation: a cohort study of 2628 Chinese women. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2010;26(5):325–332. doi: 10.3109/09513591003632100. [DOI] [PubMed] [Google Scholar]
- 26.Dokras A, Baredziak L, Blaine J, Syrop C, VanVoorhis BJ, Sparks A. Obstetric outcomes after in vitro fertilization in obese and morbidly obese women. Obstet Gynecol. 2006;108(1):61–69. doi: 10.1097/01.AOG.0000219768.08249.b6. [DOI] [PubMed] [Google Scholar]
- 27.Min JK, Claman P, Hughes E, Society of O. Gynecologists of C. Canadian F. Andrology S Guidelines for the number of embryos to transfer following in vitro fertilization. J Obstet Gynaecol Can JOGC Journal d’obstetrique et gynecologie du Canada JOGC. 2006;28(9):799–813. doi: 10.1016/S1701-2163(16)32246-0. [DOI] [PubMed] [Google Scholar]
- 28.Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, Van Steirteghem A, Devroey P. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. N Engl J Med. 2006;354(11):1139–1146. doi: 10.1056/NEJMoa053524. [DOI] [PubMed] [Google Scholar]
- 29.Papanikolaou EG, Kolibianakis EM, Tournaye H, Venetis CA, Fatemi H, Tarlatzis B, Devroey P. Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. Hum Reprod. 2008;23(1):91–99. doi: 10.1093/humrep/dem339. [DOI] [PubMed] [Google Scholar]
- 30.De Vos A, Van Landuyt L, Santos-Ribeiro S, Camus M, Van de Velde H, Tournaye H, Verheyen G. Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage embryo transfer in the first treatment cycle. Hum Reprod. 2016;31(11):2442–2449. doi: 10.1093/humrep/dew219. [DOI] [PubMed] [Google Scholar]
- 31.Practice Committee of Society for Assisted Reproductive T. Practice Committee of American Society for Reproductive M Elective single-embryo transfer. Fertil Steril. 2012;97(4):835–842. doi: 10.1016/j.fertnstert.2011.11.050. [DOI] [PubMed] [Google Scholar]
- 32.Practice Committee of American Society for Reproductive M Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril. 2012;97(4):825–834. doi: 10.1016/j.fertnstert.2011.11.048. [DOI] [PubMed] [Google Scholar]
- 33.Practice Committee of American Society for Reproductive M. Practice Committee of Society for Assisted Reproductive T Criteria for number of embryos to transfer: a committee opinion. Fertil Steril. 2013;99(1):44–46. doi: 10.1016/j.fertnstert.2012.09.038. [DOI] [PubMed] [Google Scholar]
- 34.Sunderam S, Chang J, Flowers L, Kulkarni A, Sentelle G, Jeng G, Macaluso M, Centers for Disease C, Prevention Assisted reproductive technology surveillance—United States, 2006. Morb Mortal Wkly Rep Surveill summaries. 2009;58(5):1–25. [PubMed] [Google Scholar]
- 35.Kissin DM, Kulkarni AD, Kushnir VA, Jamieson DJ, National ARTSSG. Number of embryos transferred after in vitro fertilization and good perinatal outcome. Obstet Gynecol. 2014;123(2 Pt 1):239–247. doi: 10.1097/AOG.0000000000000106. [DOI] [PMC free article] [PubMed] [Google Scholar]